Many participating companies at this event hailed from the Southwest region, presenting significant opportunities for our company's business development in that area. Simultaneously, numerous peers from other regions across the country attended to inquire about business opportunities and exchange insights. They expressed strong interest in our biodegradable PLGA materials and sustained-release microsphere products, and are highly eager to explore deeper and broader collaborations with Guangzhou DiQi in material design and formulation development.

Dr. Liu Feng, CEO of Guangzhou DiQi Pharmaceuticals Co., Ltd, delivered a keynote speech at the summit sharing insights on formulation development and optimization for improved new drugs. He presented the company's expertise in enhancing high-end formulations and modifying solid oral dosage forms, including the development journey of its injectable risperidone microspheres (4-week formulation). key quality control aspects of the biodegradable excipient poly(lactic-co-glycolic acid) (PLGA), and its application in modified long-acting implants and sustained-release injectable microspheres.

Amid the current wave of generic drug procurement and innovation, improved formulation innovation has emerged as a key focus in drug development. This conference provided an excellent opportunity for exchange, learning, and collaboration, offering clearer insights into the conceptualization, development technologies, and industrialization of improved new drugs.